ASX:IPD

ImpediMed Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume1.62 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive IPD News and Ratings via Email

Sign-up to receive the latest news and ratings for ImpediMed and its competitors with MarketBeat's FREE daily newsletter.


About ImpediMed

ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.68 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ImpediMed (ASX:IPD) Frequently Asked Questions

What stocks does MarketBeat like better than ImpediMed?

Wall Street analysts have given ImpediMed a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ImpediMed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ImpediMed's next earnings date?

ImpediMed is scheduled to release its next quarterly earnings announcement on Monday, August 23rd 2021.
View our earnings forecast for ImpediMed
.

Who are ImpediMed's key executives?

ImpediMed's management team includes the following people:
  • Mr. Richard Carreon, MD, CEO, Pres & Exec. Director
  • Mr. David Michae Adams B.Sc., J.D., BSc, Sr. VP of Operations & Strategic Planning
  • Mr. Shashi Tripathi, Chief Technology Officer
  • Mr. Dennis Schlaht, Sr. VP of R&D and Technology
  • Ms. Catherine Kingsford, Sr. VP of Medical Affairs
  • Mr. Timothy Cruickshank, Chief Financial Officer
  • Mr. Michael John Bassett, Sr. VP of Corp. & Strategic Devel.
  • Ms. Nancy T. Deisinger, VP of HR
  • Dr. Frank A. Vicini, Chief Medical Officer
  • Ms. Leanne Ralph BBus, ACIS, AAICD, Company Sec.

Who are some of ImpediMed's key competitors?

What other stocks do shareholders of ImpediMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImpediMed investors own include Bardoc Gold (BDC) and Appen (APX).

What is ImpediMed's stock symbol?

ImpediMed trades on the ASX under the ticker symbol "IPD."

How much money does ImpediMed make?

ImpediMed has a market capitalization of $0.00 and generates $6.48 million in revenue each year.

How many employees does ImpediMed have?

ImpediMed employs 69 workers across the globe.

What is ImpediMed's official website?

The official website for ImpediMed is www.impedimed.com.

How can I contact ImpediMed?

The company can be reached via phone at 61 7 3860 3700.


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.